Vasoactive intestinal peptide-oma causing refractory diarrhea in a young woman

Shankar, Nagasri; Linzay, Catherine; Rowe, Kyle

doi:10.1080/08998280.2020.1778963

Cited by 2 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VIPoma is a rare pancreatic neuroendocrine tumor causing chronic diarrhea. Most of them are malignant, and only 10% are benign [ 2 ]. They commonly occur in the tail and body of the pancreas.…”

Section: Discussionmentioning

confidence: 99%

“…They commonly occur in the tail and body of the pancreas. The typical age of presentation is the fourth and fifth decades [ 2 ]. Patients without metastatic disease have a higher five-year survival rate (>90%) compared with patients with metastatic disease (60%).…”

Section: Discussionmentioning

confidence: 99%

“…Other investigations include serum pancreatic polypeptide and chromogranin A. Functional PET imaging such as 68-Ga DOTA fusion PET/CT scans have a sensitivity of about 97% compared with CT scans [ 2 ]. The World Health Organization (WHO) classified these neuroendocrine tumors according to mitotic rate and Ki67 index.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Vasoactive Intestinal Peptide-Secreting Pancreatic Neuroendocrine Tumor: A Case Report

Thivacaren¹,

Suganthan²,

Sujanitha³

et al. 2022

Cureus

View full text Add to dashboard Cite

A 36-year-old female with chronic watery diarrhea and persistent hypokalemia for more than eight months duration eventually being diagnosed as vasoactive intestinal peptide tumor (VIPoma) clinically and histologically is presented here. The patient achieved complete recovery after starting octreotide, a somatostatin analog. She underwent a distal pancreatectomy along with the removal of the tumor at Teaching Hospital Jaffna for the permanent cure.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vasoactive Intestinal Peptide-Secreting Pancreatic Neuroendocrine Tumor: A Case Report

Thivacaren¹,

Suganthan²,

Sujanitha³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…Age at diagnosis is 50-55 years and nearly 40%-90% will have hepatic metastasis at the time of diagnosis. Five-year survival is 60% in patients with metastatic disease and 94% in those without[ 49 , 50 ]. Diagnosis is characterised by raised VIP levels in a patient with typical watery diarrhoea (specificity 100%).…”

Section: Clinical Features Of Gep-nens With Hormone Hypersecretionmentioning

confidence: 99%

Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot

Fernandez¹,

Agarwal²,

Pottakkat³

et al. 2021

WJGS

View full text Add to dashboard Cite

Our understanding about the epidemiological aspects, pathogenesis, molecular diagnosis, and targeted therapies of neuroendocrine neoplasms (NENs) have drastically advanced in the past decade. Gastroenteropancreatic (GEP) NENs originate from the enteroendocrine cells of the embryonic gut which share common endocrine and neural differentiation factors. Most NENs are well-differentiated, and slow growing. Specific neuroendocrine biomarkers that are used in the diagnosis of functional NENs include insulin, glucagon, vasoactive intestinal polypeptide, gastrin, somatostatin, adrenocorticotropin, growth hormone releasing hormone, parathyroid hormone-related peptide, serotonin, histamine, and 5-hydroxy indole acetic acid (5-HIAA). Biomarkers such as pancreatic polypeptide, human chorionic gonadotrophin subunits, neurotensin, ghrelin, and calcitonin are used in the diagnosis of non-functional NENs. 5-HIAA levels correlate with tumour burden, prognosis and development of carcinoid heart disease and mesenteric fibrosis, however several diseases, medications and edible products can falsely elevate the 5-HIAA levels. Organ-specific transcription factors are useful in the differential diagnosis of metastasis from an unknown primary of well-differentiated NENs. Emerging novel biomarkers include circulating tumour cells, circulating tumour DNA, circulating micro-RNAs, and neuroendocrine neoplasms test (NETest) (simultaneous measurement of 51 neuroendocrine-specific marker genes in the peripheral blood). NETest has high sensitivity (85%-98%) and specificity (93%-97%) for the detection of gastrointestinal NENs, and is useful for monitoring treatment response, recurrence, and prognosis. In terms of management, surgery, radiofrequency ablation, symptom control with medications, chemotherapy and molecular targeted therapies are all considered as options. Surgery is the mainstay of treatment, but depends on factors including age of the individual, location, stage, grade, functional status, and the heredity of the tumour (sporadic vs inherited). Medical management is helpful to alleviate the symptoms, manage inoperable lesions, suppress postoperative tumour growth, and manage recurrences. Several molecular-targeted therapies are considered second line to somatostatin analogues. This review is a clinical update on the pathophysiological aspects, diagnostic algorithm, and management of GEP NENs.

show abstract

Vasoactive intestinal peptide-oma causing refractory diarrhea in a young woman

Cited by 2 publications

References 16 publications

Vasoactive Intestinal Peptide-Secreting Pancreatic Neuroendocrine Tumor: A Case Report

Vasoactive Intestinal Peptide-Secreting Pancreatic Neuroendocrine Tumor: A Case Report

Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot

Contact Info

Product

Resources

About